What is the survival period for targeted therapy in lung adenocarcinoma?

Survival time for patients with lung adenocarcinoma undergoing targeted therapy is approximately 1 to 5 years, with actual survival periods varying due to individual differences. Detailed analysis is as follows:

Some patients may be highly sensitive to targeted drugs, resulting in significant treatment effects. Due to this drug sensitivity and favorable therapeutic outcomes, tumor growth may be effectively controlled, and in some cases, tumor downstaging may occur, thereby providing an opportunity for surgical treatment. Under these favorable conditions, the patient's survival time may be extended to 3–5 years or even longer. These patients typically achieve improved quality of life and prolonged survival with the help of targeted therapy.

Conversely, for patients who are not sensitive to targeted drugs or have developed drug resistance, the effectiveness of targeted therapy may be limited, and the tumor may continue to progress, resulting in a relatively shorter survival period. In such cases, survival time may be approximately one year. However, even when facing these challenges, patients can still attempt alternative treatment strategies, such as chemotherapy or radiotherapy, under the guidance of a physician to strive for better treatment outcomes and longer survival.

Patients with better general health and stronger immune systems are more likely to respond favorably to targeted therapy. Additionally, patients with severe comorbidities may have more difficulty tolerating targeted therapy or may require more complex treatment strategies, which can impact survival time.

Patients should maintain healthy lifestyle habits and follow scientifically sound dietary practices in their daily lives, actively optimizing their physical condition to enhance treatment efficacy.